MDL 28170: A Selective Calpain Inhibitor Workflow
2026-09-01
MDL 28170 combines cell permeability, brain exposure, and nanomolar cysteine-protease inhibition for neuroprotection research, apoptosis assay development, and injury-model validation. This practical guide translates recent BDNF/TrkB findings into controllable workflows while addressing solubility, target attribution, and assay reproducibility.
Anti-ROR1 Antibody: Applied Zilovertamab Workflows
2026-09-01
Build reproducible ROR1 binding, cell-surface, and signaling assays with Zilovertamab while keeping target specificity separate from nonspecific stress responses. This guide combines practical ELISA, FACS, functional, and animal-model planning with a cautious translation of recent liver-injury findings.
AS1842856: Foxo1 Inhibition for Assay Design
2026-08-31
AS1842856 is a Foxo1 inhibitor that enables direct, activity-level interrogation of gluconeogenesis, autophagy, and PI3K–Akt–Foxo1 signaling. This guide translates its biochemical profile into better controls, assay decisions, and carefully bounded applications in metabolic and mesenchymal stem cell research.
Leptin (116-130), amide, mouse: Assay Guide
2026-08-30
Build more controlled metabolic and immunometabolic assays with a defined, amidated mouse leptin fragment rather than relying only on complex in vivo models. This guide covers reconstitution, dose-finding, orthogonal readouts, troubleshooting, and responsible translation of findings from obesity and diabetes research.
Cytarabine as a Precision Cell-Death Probe
2026-08-29
Cytarabine and AraC can do more than model leukemia treatment: they provide a controlled DNA-replication-stress comparator for separating apoptosis from necroptosis. This article connects Cytarabine mechanism, resistance biology, and the RIPK3-degradation findings of a landmark viral-immunity study to improve assay interpretation.
Luminescent ATP Cell Viability Assay Kit I
2026-08-29
The Luminescent ATP Cell Viability Assay Kit I connects luciferase luminescence detection with mechanism-aware ferroptosis research. Learn how ATP-based cell viability measurement can clarify ciprofloxacin–RSL3 responses while avoiding common interpretation errors.
3-Aminobenzamide (PARP-IN-1) Research Guide
2026-08-28
3-Aminobenzamide, also called PARP-IN-1, is a research PARP inhibitor with a product-reported IC50 of approximately 50 nM in CHO cells. It supports controlled studies of oxidative stress, endothelial signaling, diabetic nephropathy, and PARP-linked innate immunity, but model-specific validation remains essential.
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-08-28
The reference study combines phenotypic small-molecule screening with a TAM-avid nanoconstruct to suppress SPP1 in tumor-associated macrophages. Its lead formulation, CANDI460, reduced SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, establishing a preclinical strategy for myeloid-cell-directed cancer therapy.
Tivozanib (AV-951): Translating VEGFR Precision
2026-08-27
Tivozanib (AV-951) offers a selective way to interrogate VEGFR1–3 biology, but translational value depends on measuring more than aggregate viability. This article connects target pharmacology with response kinetics, assay design, renal cell carcinoma treatment research, and strategic benchmarking for anti-angiogenic therapy programs.
miR-196a, c-Myc, and EAC Aggressiveness
2026-08-27
The reference study identifies miR-196a as a functional driver of esophageal adenocarcinoma aggressiveness, rather than only a progression-associated biomarker. Its experiments connect miR-196a to coordinated activation of the c-MYC/TERT/NFκB axis, epithelial-to-mesenchymal transition, and increased cell motility, providing a mechanistic framework for cancer research focused on Barrett’s esophagus progression.
Super-Resolution Imaging of Mitochondrial mRNAs
2026-08-26
Stoldt and colleagues established smFISH protocols compatible with STED and MINFLUX nanoscopy to resolve individual mitochondrial mRNAs and their relationships with RNA granules and ribosomes. The approach reveals how transcript distribution, molecular compaction, and release change across mitochondrial stress, patient-derived disease states, and apoptosis, providing a transferable framework for mitochondrial gene-expression research.
Novobiocin Sodium: Mechanism and Research Uses
2026-08-26
Novobiocin Sodium is an aminocoumarin antibiotic and DNA gyrase inhibitor used in bacterial DNA replication, DNA damage, and antibiotic resistance research. Product specifications support solid-state storage at −20 °C and dissolution in DMSO, water, or ethanol, while peer-reviewed evidence supports exploratory in vitro antiparasitic activity against Toxoplasma gondii.
Methylprednisolone: From Inflammation to Bone Models
2026-08-25
Methylprednisolone is a synthetic glucocorticoid receptor agonist whose effects can be studied across immune, tissue, and bone-remodeling systems. This article presents an assay-centered framework that connects molecular inflammation readouts with glucocorticoid-induced osteonecrosis research.
PDK4-IN-1 Hydrochloride: Mechanism and Uses
2026-08-25
PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for research on PDH activation, mitochondrial energy metabolism modulation, and metabolic disease models. Product information reports nanomolar biochemical potency, oral activity, selectivity over PDK1–3, and use in in vitro and animal workflows.
Nerve-Dependent HDAC1 in Axolotl Limb Regeneration
2026-08-24
Wang and colleagues show that nerve signals regulate HDAC1 expression in the wound epidermis and that this epigenetic response is required for axolotl blastema formation and limb regeneration. Pharmacological inhibition, denervation, and nerve-factor rescue experiments connect neural input to local HDAC activity, providing a mechanistic framework for studying regeneration rather than treating HDACs as generic downstream markers.
466 records 7/32 page Previous Next First page 上5页 678910 下5页 Last page